Thyrocare Technologies Ltd - 539871 - Board declares Interim Dividend
Thyrocare Technologies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 29, 2022, inter alia, has decided to declare an interim dividend at the rate of Rs. 15.00 (Rupees Fifteen Only) per share (150% of the face value of Rs. 10/- each) for the financial year 2021-22. Thyrocare Technologies Ltd - 539871 - The Board Has Fixed, Thursday 12Th May 2022 As The Record Date For The Purpose Of Determining The Entitlement Of Shareholders For The Interim Dividend
The Board has fixed, Thursday 12th May 2022 as the record date for the purpose of determining the entitlement of shareholders for the interim dividend Thyrocare Technologies Ltd - 539871 - Stand-Alone And Consolidated Audited Financial Results For The Quarter And The Financial Year Ended March 31, 2022
This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the Audited Financial Results (Stand-alone and Consolidated) for the Financial Year ended March 31, 2022 and have also decided to declare an interim dividend at the rate of Rs. 15.00 (Rupees Fifteen only) per share (150% of the face value of Rs. 10/- each) for the financial year 2021-22. The Board has fixed, Thursday 12th May 2022 as the record date for the purpose of determining the entitlement of shareholders for the interim dividend. Thyrocare Technologies Ltd - 539871 - Board Meeting Outcome for Outcome Of Board Meeting Held On 29-04-2022
This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the Audited Financial Results (Stand-alone and Consolidated) for the Financial Year ended March 31, 2022 and have also decided to declare an interim dividend at the rate of Rs. 15.00 (Rupees Fifteen only) per share (150% of the face value of Rs. 10/- each) for the financial year 2021-22. The Board has fixed, Thursday 12th May 2022 as the record date for the purpose of determining the entitlement of shareholders for the interim dividend. Thyrocare Technologies Ltd - 539871 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayThyrocare Technologies Ltd 2CINL85110MH2000PLC123882 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Ramjee Dorai Designation: Company Secretary and Compliance Officer EmailId: ramjee.d@thyrocare.com Name of the Chief Financial Officer: Sachin Salvi Designation: Chief Financial Officer EmailId: sachin.salvi@thyrocare.com Date: 29/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Thyrocare Technologies Ltd - 539871 - Revised Approval Letters Of National Stock Exchange Of India Limited And BSE Limited For Reclassification Of Outgoing Promoter And Promoter Group Shareholders
Please refer to our letter dated March 17, 2022 filed with you, pursuant to the provisions of Regulation 30 and Regulation 31(8)(d) of SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 ('LODR'), intimating that the Company has received approval from the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') for reclassification of the outgoing Promoters and Promoter Group shareholders from Promoter category to public category in accordance with the Regulation 31A (10) of LODR . Thyrocare Technologies Ltd - 539871 - Board to consider FY22 results & Final Dividend on April 29, 2022
Thyrocare Technologies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on April 29, 2022, inter alia, to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter / financial year ended March 31, 2022, to consider recommending final dividend, if any, for the financial year 2021-22, and to consider granting of Employee Stock Options to the eligible employees for the financial year ended March 31, 2022. Thyrocare Technologies Ltd - 539871 - Board Meeting Intimation for Intimation Under Regulation 29 (1) (A) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2022 ,inter alia, to consider and approve Audited Stand-alone and Consolidated Financial Results of the Company for the quarter / financial year ended March 31, 2022, to consider recommending final dividend, if any, for the financial year 2021-22, and to consider granting of Employee Stock Options to the eligible employees for the financial year ended March 31, 2022. Thyrocare Technologies Ltd - 539871 - Submission Of Compliance Certificate In Terms Of Regulation 40 (9) Of Securities & Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Submission of Compliance Certificate in terms of Regulation 40 (9) of Securities & Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015,for the year ended March 31, 2022.